TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00726609

Intervention type: DRUG
Intervention: Posaconazole
Description: The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.
Study: NCT00746551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferli-6® (Continental Pharm co., ltd.)
Description: In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer® (Vifor AG, St. Gallen, Switzerland)
Description: Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
Study: NCT04014777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM621
Description: NGM621 Dose 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM621
Description: NGM621 Dose 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM621
Description: NGM621 Dose 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM621
Description: NGM621 Dose 4
Study: NCT00909168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLAIMy - Fluda, Ida, Ara-C, Mylotarg
Description: FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5~ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5~IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5~GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6
Study: NCT04264208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga RM2.
Description: PET radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga RM2.
Description: PET radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga PSMA11
Description: PET radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga PSMA11
Description: PET radiopharmaceutical

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: PET/MR scanner by GE healthcare

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: PET/MR scanner by GE healthcare
Study: NCT04014530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren + Pembrolizumab
Description: Ataluren and Pembrolizumab combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren + Pembrolizumab
Description: Ataluren and Pembrolizumab combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren + Pembrolizumab
Description: Ataluren and Pembrolizumab combination therapy
Study: NCT03054428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
Study: NCT02346734

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Sclerosis Home Automated Telemanagement (MS HAT) system
Study: NCT03142945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Physical therapy-based interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDT based physical therapy
Description: MDT based physical therapy
Study: NCT01404910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apheresis using Liposorber LA-15 System
Description: The Liposorber LA-15 Device is a dextran sulfate cellulose column, one of several currently approved in Europe and United States for pheresis of lipoproteins in the treatment of familial hypercholesterolemia. Such devices have been in use for over 30 years. Published experience in pregnant women with familial hypercholesterolemia suggests that lipoprotein pheresis can be safely used in pregnancy after appropriate individual benefit/risk assessment for both mother and fetus is considered. The Liposorber LA-15 system selected for this trial has been evaluated for its ability to efficiently and selectively remove sFlt-1 in vitro.
Study: NCT03533751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etokimab
Description: Humanized monoclonal antibody, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etokimab
Description: Humanized monoclonal antibody, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etokimab
Description: Humanized monoclonal antibody, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etokimab
Description: Humanized monoclonal antibody, administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT00909064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux Sodium (Arixtra)
Description: 2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
Study: NCT00331565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Gastric bypass, duodenal switch and sleeve surgery
Study: NCT03856697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abivertinib Maleate Capsules
Description: patients receive the test drug (Abivertinib maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gefitinib Tablets
Description: patients receive the test drug (Placebo Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib Tablets
Description: patients receive the control drug (Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Abivertinib Maleate Capsules
Description: patients receive the control drug (Placebo Abivertinib Maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
Study: NCT03479112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flashcards
Description: Participants will be provided with Flashcards depicting how to correctly apply a tourniquet to an extremity wound.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio-kit
Description: Participants will be provided with an audio-kit with accompanying visual cues describing and depicting how to correctly apply a tourniquet to an extremity wound.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-Con training
Description: Participants will undergo the Bleeding control for the injured (B-Con) basic course.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-Con training retention
Description: Evaluation of retention of Bleeding Control for the injured basic course
Study: NCT01858870

Intervention type: DRUG
Intervention: lacosamide
Description: routine clinical practice
Study: NCT03863860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib capsules
Description: Fluzoparib capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsule
Study: NCT02920580

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in this group will be treated according to usual care, which may include extubation (removal of endotracheal tube) or insertion of a tracheostomy, timed according to physicians' discretion. The inclusion of this arm will allow prompt extubation to be compared to usual practice, which often involves further observation and delayed decision-making due to clinician uncertainty about the optimal airway management strategy. Incorporation of usual care arms has been promoted as a design feature to improve the safety and interpretability of critical care clinical trials.
Study: NCT01355900

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total knee arthroplasty performed under tourniquet
Description: Comparison of the different tourniquet tactics.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total knee arthroplasty performed under tourniquet
Description: Comparison of the different tourniquet tactics.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total knee arthroplasty performed under tourniquet
Description: Comparison of the different tourniquet tactics.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total knee arthroplasty performed under tourniquet
Description: Comparison of the different tourniquet tactics.
Study: NCT03939559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static, dynamic and functional balance exercises
Description: In the first group (G1), 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static, dynamic and functional balance exercises with dual task
Description: In the second group (G2), 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks.
Study: NCT03181789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p24CE1/2 pDNA Vaccine
Description: Administered bilaterally using the Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p55^gag pDNA Vaccine
Description: Administered bilaterally using the TDS-IM EP device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p55^gag pDNA Vaccine
Description: Administered bilaterally using the TDS-IM EP device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 pDNA Adjuvant
Description: Administered bilaterally using the TDS-IM EP device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 pDNA Adjuvant
Description: Administered bilaterally using the TDS-IM EP device

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered bilaterally using the TDS-IM EP device

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered bilaterally using the TDS-IM EP device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
Description: The TDS-IM EP device will be used to administer study product(s).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
Description: The TDS-IM EP device will be used to administer study product(s).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
Description: The TDS-IM EP device will be used to administer study product(s).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
Description: The TDS-IM EP device will be used to administer study product(s).
Study: NCT05841329

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: High-definition tDCS (HD-tDCS, 4×1 montage, with 1 anode and 4 cathodes, (Soterix Medical, New York, NY, USA) was applied with battery-driven electrical stimulator (2001\&4×1-C3A). The center electrode was anode and placed over FPz (according to the EEG 10-20 system in order to target the medial prefrontal cortex). The reference electrodes were cathodes and placed over AF7, AF8, F3, F4(see fig. 3). Participants were randomized to receive 20 minutes of active(1.5mA) or sham (0 mA) tDCS in a single-blind design. In order to ensure that participants can gradually adapted to the current change, there was a 15-second current rising process before the stimulation and, a 15-second current falling process after the stimulation. For sham tDCS, the device was automatically turned off after current reached 1.5 mA, thus providing 30s of ramping current stimulation, which made it difficult for participants to distinguish which kinds of stimulation they received.
Study: NCT02964130

Intervention type: OTHER
Group type: OTHER
Intervention: No name
Study: NCT01085643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 24mcg PO taken once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24mcg placebo capsule taken once
Study: NCT05841329

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality exposure therapy
Description: The VRET was adapted on the basis of Öst's single exposure treatment paradigm and conducted by experienced psychotherapists following a standard exposure treatment manual.. An exposure therapy was divided into three parts: psychological education, exposure intervention and summary. Each scene started with a 10-min psychological education followed up with the tDCS stimulation. In exposure trail, participants ought to take an elevator to 100th, observe the environment and look down on the platform. The psychotherapist guided participants to be exposed to the VR environment and helped them experience the process of anxiety decline in the exposure trail.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: virtual reality exposure therapy
Description: The VRET was adapted on the basis of Öst's single exposure treatment paradigm and conducted by experienced psychotherapists following a standard exposure treatment manual.. An exposure therapy was divided into three parts: psychological education, exposure intervention and summary. Each scene started with a 10-min psychological education followed up with the tDCS stimulation. In exposure trail, participants ought to take an elevator to 100th, observe the environment and look down on the platform. The psychotherapist guided participants to be exposed to the VR environment and helped them experience the process of anxiety decline in the exposure trail.
Study: NCT01555476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
Study: NCT02943772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local hypothermia
Description: Cooled brick

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control brick
Study: NCT03644017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WRAPSODY Stent Graft Placement
Description: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein
Study: NCT01298947

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems
Description: comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems
Description: comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries
Study: NCT00943436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Session
Description: This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Exercise Session will consist of the participant coming into the lab and completing 45 min bout of exercise on an exercise bike, followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum.
Study: NCT01555476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
Study: NCT02064348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.
Study: NCT00943436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Session
Description: This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Exercise Session will consist of the participant coming into the lab and completing 45 min bout of exercise on an exercise bike, followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest Session
Description: This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Rest Session will consist of the participant coming into the lab and completing a 45 min period of reading followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest Session
Description: This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Rest Session will consist of the participant coming into the lab and completing a 45 min period of reading followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum.
Study: NCT03728569

Intervention type: OTHER
Group type: OTHER
Intervention: Vanicream Moisturizing Skin Cream
Description: Vanicream Moisturizing Skin Cream daily application

Intervention type: OTHER
Group type: OTHER
Intervention: Vanicream Moisturizing Skin Cream
Description: Vanicream Moisturizing Skin Cream daily application

Intervention type: OTHER
Group type: OTHER
Intervention: Vanicream Cleansing Soap
Description: Vanicream Cleansing Soap daily use

Intervention type: OTHER
Group type: OTHER
Intervention: Vanicream Cleansing Soap
Description: Vanicream Cleansing Soap daily use
Study: NCT03880747

Intervention type: PROCEDURE
Intervention: Vagus nerve-preserving distal gastrectomy
Description: Laparoscopic distal gastrectomy with the preservation of the celiac and hepatic branch of the vagus nerve.
Study: NCT03106077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Given IV
Study: NCT00949442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine (HOE901) [Lantus]
Description: 100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: tablets of 1 and 2 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: tablets of 1 and 2 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human insulin [NPH]
Description: 100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
Study: NCT03548077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWERPLAY
Description: All men from participating worksites are invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)
Study: NCT00900939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat, vegan diet
Description: Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.